Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
06-24 | Stock markets up; in Germany business morale falls again | AN |
06-24 | Stock exchanges up; on Mib pushes banking sector | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.13 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.54 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 8.01B | - | ||
-4.92% | 182B | C+ | ||
-3.70% | 103B | C | ||
-5.29% | 66.94B | A | ||
+10.99% | 46.73B | B- | ||
-7.70% | 45.14B | B- | ||
+6.64% | 41.57B | B+ | ||
+15.96% | 30.48B | B | ||
+14.08% | 24.26B | A- | ||
-6.63% | 23.58B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AMP Stock
- 0N61 Stock
- Ratings Amplifon